OpenAI announced that it had acquired Orchestra Bio, whose AI agents help manage drug development programs. It plans to fold Orchestra’s team and platform into its Rosalind tools, but did not disclose the price or say when the agents would be available there.
Orchestra’s agents track how setbacks affect tasks and deadlines and compare possible responses. Scientists and program leaders make the final decisions.
